Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients
Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Jan 4, 2018
Trial Information
Current as of June 13, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Branch retinal vein or central retinal vein occlusion Previous at least 3 intravitreal antiVEGF injection Macular edema in SD-OCT CMT = \>250 microns BCVA equal or lesd than 20/40
- Exclusion Criteria:
- • Moderate or severe corneal opacity Significant cataract obscuring retinal exam or OCT Glaucoma History of vitreoretinal surgery Diabetic retinopathy Macular disease (AMD,ERM,VMT Kidney or Liver disease Uncontrolled or moderate or severe Anemia Uncontrolled hypertention
About Shahid Beheshti University Of Medical Sciences
Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, is a leading institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to medical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical practices. With a multidisciplinary approach, it collaborates with healthcare professionals and researchers to explore new treatments and interventions, contributing significantly to the global body of medical knowledge. The institution is dedicated to upholding the highest ethical standards in research, ensuring the safety and well-being of participants while fostering a culture of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials